Ultragenyx (RARE), Solid Biosciences (SLDB) Announce Strategic Collaboration to Develop and Commercialize New Gene Therapies for DMD

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. IBM
2. PRIM
3. META
4. KFY
5. ABBV
6. MU
7. DPZ
8. NAVN
9. DFTX
10. NVEC

Go back to Ultragenyx (RARE), Solid Biosciences (SLDB) Announce Strategic Collaboration to Develop and Commercialize New Gene Therapies for DMD

Ultragenyx Pharma (RARE) Tops Q3 EPS by 14c, Revenues Beat

October 27, 2020 4:45 PM EDT

Ultragenyx Pharma (NASDAQ: RARE) reported Q3 EPS of ($1.13), $0.14 better than the analyst estimate of ($1.27). Revenue for the quarter came in at $81.5 million versus the consensus estimate of $53.89 million.

Third quarter 2020 total revenue of $81.5 million and Crysvita revenue of $37.3 millionIncreased lower end of... More

Solid Biosciences (SLDB) Climbs 26% Following Pact with Ultragenyx Pharma (RARE) in DMD

October 23, 2020 8:18 AM EDT

Solid Biosciences (NASDAQ: SLDB) Climbs 26% Following Pact with Ultragenyx Pharma (NASDAQ: RARE) in DMD

Earlier Ultragenyx, Solid Biosciences Announce Strategic Collaboration to Develop and Commercialize New Gene Therapies for DMD... More